BioSpace News Archive

Sutro Biopharma presented Phase I data at (AACR) showing that its lead compound, STRO-002, not only kills the tumor but also elicits immunogenic cell death.

Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen’s differentiated PARP inhibitor RP12146, indicates a superior haematological safety profile that the company expects will translate through ongoing clinical trials.

PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric therapies targeting eIF4E, announced it will present pre-clinical data on the company’s eIF4E program for ER+ breast cancer in a poster at the American Association for Cancer Research Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans, LA.